drugset
drugset / Trial / NCT05224492

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

NCT05224492 ↗

Phase 4 Unknown 20 enrolled Sunshine Specialty Health Care
RandomizedParallel-groupSingle-blindTreatment

Summary

Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.

Timeline

Start
2022-02-21
Primary completion
2022-07-21
Completion
2022-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulforaphane Small molecule 40 mg —

Indications

HIV infectious disease